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Abstract 
G-protein coupled receptor 119 (GPR119) expression in pancreatic β-cells and 
intestinal L-cells is a potential therapeutic target for treating type 2 diabetes. A natural GPR119 
agonist oleoylethanolamide is well known to enhance a glucose stimulated insulin secretion 
(GSIS) and glucagon like peptide-1 (GLP-1) secretion by elevating intracellular cAMP levels. 
In the present study, a glucose lowering effect of the GPR119 agonist, JTP-109192 leading to 
improvement of insulin sensitivity was examined in Zucker Fatty (ZF) rats. We investigated 
the in vitro effects of JTP-109192 on GSIS in the rat pancreatic β-cell line (INS1E) cells and 
on GLP-1 secretion in the murine enteroendocrine cell line (GLUTag) cells. We also 
investigated the effect of JTP-109192 on GSIS in Sprague-Dawley (SD) rats with single 
administration and its effect on glucose metabolism in ZF rats with repeated administration 
once daily for about 6 weeks. After repeated administration, the hyperinsulinemic euglycemic 
glucose clamp test was performed to evaluate insulin sensitivity. JTP-109192 increased 
intracellular cAMP levels (EC50 value: 3.6 nmol/L) and enhanced GSIS in the INS1E cells and 
GLP-1 secretion in GLUTag cells. In SD rats, a single administration of JTP-109192 enhanced 
GSIS at high blood glucose levels. The repeated administrations in ZF rats improved glucose 
metabolism without lack of drug efficacy (tachyphylaxis) and increased glucose infusion rates 
due to improvement of insulin sensitivity. 
 
Keywords: G-protein coupled receptor 119, Diabetes, glucose clamp, insulin sensitivity, 
Zucker Fatty rat. 
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1. Introduction 
According to the World Health Organization (WHO), the number of adults with diabetes 
world-wide in 2016 is over 400 million people, due to the changes of lifestyle such as 
westernization of eating habits, excessive carbohydrate intake and reduction in the amount of 
exercise.1 It is expected that the number of diabetic patients world-wide will increase further. 
Diabetes is a risk factor for macrovascular diseases, such as heart attack or stroke, or other 
microvascular complications such as retinopathy, peripheral neuropathy, nephropathy or 
diabetic foot. A variety of drugs such as sulfonylurea (SU), dipeptidyl peptidase-4 (DPP-4) 
inhibitor, fast acting insulin secretagogue, biguanide (BG), thiazolidinedione (TZD), sodium 
glucose cotransporter 2 (SGLT 2) inhibitor are on the trends of diabetes remedies. However, 
hypoglycemia, weight gain or dehydration has been reported for their adverse effects. Therefore, 
the unmet medical needs still may exist for medicine which exhibits the good efficacy and less 
adverse effects. On the other hand, the natural history of type 2 diabetes involves the 
progression of impaired glucose tolerance (IGT) subjects turn to diabetic mellitus characterized 
by impaired insulin secretion2 and development of insulin resistance of peripheral tissue.3 
Therefore, a therapeutic strategy that addresses the enhancement of glucose stimulated insulin 
secretion (GSIS) and leading to improvement of insulin resistance would be a better treatment 
for impaired insulin secretion and insulin resistance.  
The target molecule in our study, G-protein coupled receptor 119 (GPR119) have been 
identified as Gs-coupled protein receptor. That is mainly expressed in the pancreas and in the 
intestinal L cells and its activation increases the levels of intracellular cyclic adenosine 
monophosphate (cAMP).4 The Zucker Fatty (ZF) rats are a widely used animal model of insulin 
resistance and have a mutation in the leptin receptor gene (Leprfa),5 expressing 
hyperinsulinemia, hypertriglyceridemia and impaired glucose tolerance associated with obesity 
due to polyphagia.6 Despite a great effort of pharmaceutical companies, no GPR119 agonist 
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has been entered phase 3 clinical trial. GSK1292263 failed to increase blood GLP-1 level or 
decrease plasma glucose level in the phase 2 clinical trial.7 Significant decrease in plasma 
glucose level was not observed with JNJ-38431055 treatment.8 The lack of drug efficacy after 
repeated administration (tachyphylaxis) may provide one probable explanation for the 
termination. However, recent report suggested that the GPR119 agonists promote glucagon 
secretion under hypoglycemic conditions and this action is abolished in GPR119 knockout 
mice.9 Therefore, from a new aspect, the drug discovery research on GPR119 agonist still seems 
to be active. 
In the present study, we characterized effects of single treatment with JTP-109192, a novel 
small-molecule agonist of GPR119, on insulin secretion in the rat pancreatic β-cell line (INS1E) 
cells and GLP-1 secretion in the murine enteroendocrine cell line (GLUTag) cells. We also 
characterized the effect of JTP-109192 with single administration on GSIS in SD rats with 
various blood glucose levels using hyperglycemic clamp technique and the effect with repeated 
administrations in ZF rats on glucose metabolism using glucose tolerance test. At the end of the 
period of repeated administration, the insulin sensitivity was evaluated using hyperinsulinemic 
euglycemic clamp technique. 
 
2. Results 
2.1 GPR119 agonist activity of JTP-109192 
In this assay, we examined the human, rat and murine GPR119 agonist activity of JTP-109192, 
4-[5-(3,3-dimethyl-2-oxa-spiro[4.5] dec-8-yl)-pentyloxy]-N,N-dimethyl-benzamide (Fig. 1A) 
by measuring cellular cAMP levels in HEK293 cells, that stably express the GPR119 protein 
of each species. JTP-109192 significantly increased cAMP levels in a dose-dependent manner. 
The EC50 values which were determined as the concentration of JTP-109192 required to achieve 
50% of the maximal oleoylethanolamide (OEA) stimulated response in human, rat and mouse 
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were 3.6 ± 0.2 nmol/L, 4.5 ± 0.2 nmol/L and 5.2 ± 0.2 nmol/L, respectively (Fig. 1B–D). 
 
2.2 Effects of JTP-109192 on insulin secretion in INS1E cells and GLP-1 secretion in 
GLUTag cells. 
We examined the insulinotropic effect of JTP-109192 in INS1E cells in the presence of 11.2 or 
3.3 mmol/L glucose. At 1 μmol/L, JTP-109192 exerted a 1.9-fold increase in insulin secretion 
as compared with DMSO alone in the presence of 11.2 mmol/L glucose (56.9 ± 11.7 ng/mL vs. 
29.6 ± 8.0 ng/mL, P < 0.05), while JTP-109192 did not have any effect in the presence of 
3.3 mmol/L glucose (Fig.2 A). We then examined the effect of JTP-109192 on GLP-1 secretion 
in GLUTag cells. GLP-1 secretion was significantly increased by JTP-109192 from 0.1 μmol/L. 
At 10 μmol/L, 5.6-fold increase by JTP-109192 was observed as compared with DMSO alone 
(401.0 ± 40.7 ng/mL vs. 113.3 ± 46.9 ng/mL, P < 0.01) (Fig.2 B). 
 
2.3 Effects of JTP-109192 on insulin secretion in SD rats after single administration using 
the hyperglycemic clamp technique. 
After overnight fasting, cannulated SD rats (7 weeks old) were administered orally 0.5% MC 
(vehicle) or JTP-109192 (10 mg/kg). After 30 minutes, 25% glucose solution was infused via 
cannula into jugular vein. By adjusting the infusion rate of the glucose solution, the blood 
glucose levels in both groups were elevated and were maintained at approximately 250 mg/dL 
for the first 60 minutes, and at 400 mg/dL for the following 60 minutes, respectively (Fig. 3A). 
The plasma insulin levels in the vehicle group were increased following to the elevation of the 
blood glucose levels, and a biphasic insulin secretion was observed at both blood glucose levels 
(Fig. 3B). The plasma insulin levels in the JTP-109192 group were also increased and remained 
higher than the vehicle group throughout the glucose infusion period. The first and the second 
phase insulin secretions in the JTP-109192 group were significantly enhanced at both blood 
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glucose levels as compared with the vehicle group. The first phase insulin secretion was 
32.2 ± 7.2 ng/mL·min vs. 12.3 ± 3.3 ng/mL·min (P < 0.01) at 250 mg/dL and 
100.4 ± 10.7 ng/mL·min vs. 28.9 ± 8.5 ng/mL·min (P < 0.01) at 400 mg/dL. The Second phase 
insulin secretion 444.0 ± 54.8 ng/mL·min vs. 122.3 ± 22.6 ng/mL·min (P < 0.01) at 250 mg/dL, 
and 1898.1 ± 547.6 ng/mL·min vs. 393.4 ± 95.3 ng/mL·min (P < 0.01) at 400 mg/dL (Fig. 3C, 
3D). 
The plasma GLP-1 levels after hyperglycemic clamp test in both portal and peripheral vein 
were significantly higher in the JTP-109192 group than the vehicle group (portal: 
31.9 ± 5.4 ng/mL vs. 17.4 ± 2.4 ng/mL, [P < 0.05]; peripheral: 10.0 ± 1.4 ng/mL vs. 
8.7 ± 1.0 ng/mL [P < 0.01; Fig. 3E]). 
 
2.4 Effects of repeated administration of JTP-109192 in Zucker Fatty rats. 
During 6 weeks of repeated administration of JTP-109192 (10 mg/kg) or vehicle, the body 
weight was increased and there were no differences between both groups (Fig. 4A). The plasma 
glucose, plasma insulin and blood HbA1c levels were lower in JTP-109192 treated group than 
the vehicle group (Fig. 4B–D). 
 
2.5 Effects of JTP-109192 on glucose metabolism in Zucker Fatty rat after single and 
repeated administration in intraperitoneal glucose tolerance tests. 
The plasma glucose levels of vehicle and JTP-109192 treated groups were increased after single 
glucose administration (Fig. 5A). The glucose levels at the dose of 10 mg/kg JTP-109192 group 
were remarkably reduced after glucose administration as compared with the vehicle or JTP-
109192 3 mg/kg group. The plasma insulin levels and insulinogenic index in the 10 mg/kg 
group were also increased and were higher than the vehicle or 3 mg/kg group after glucose 
administration (Fig. 5B, 5C). After 6 weeks of repeated administration, the glucose and insulin 
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levels in the JTP-109192 10 mg/kg group were reduced (Fig. 6A, 6B) and insulinogenic index 
after glucose administration was significantly higher than the vehicle group (Fig. 6C). 
 
2.6 Effects of repeated administration of JTP-109192 in Zucker Fatty rat in 
hyperinsulinemic euglycemic clamp test. 
After 6 weeks of repeated administration, the plasma GLP-1 levels before hyperinsulinemic 
euglycemic clamp test in peripheral vein in the JTP-109192 10 mg/kg group were tended to be 
higher than the vehicle group (3.3 ± 0.3 ng/mL vs. 2.6 ± 0.7 ng/mL, P < 0.1) (Fig. 7A). The 
glucose infusion rate in JTP-109192 group was significantly higher than the vehicle group 
(7.9 ± 2.5 mg/kg/min vs. 3.3 ± 3.5 mg/kg/min, P < 0.05) (Fig. 7B). With further investigation, 
we found that the increase in glucose infusion rate in JTP-109192 group was due to suppression 
of hepatic gluconeogenesis (20.4 ± 21.0% vs. 42.1 ± 18.3%, P < 0.05) (Fig. 7C).  
 
3. Discussion 
In this decade, various strategies focusing on GPCRs to treat diabetes, such as GPR40, 
other FFARs, GIPR, GLPR, glucagon receptor, GPR55, GPR39 and GPR21, have been reported. 
According to GPCRome analysis, GPR119 appears to be suitable as a drug target to stimulate 
insulin secretion as compared with other GPCRs.10 Recently, GPR119 agonists, GSK1292263 
and PSN119-1, have been showed an increase of glucagon secretion under hypoglycemic 
conditions in rats.9 The enhancement of glucagon secretion was directly observed in immune 
glucagon-positive cells, and was disappeared in GPR119 knockout mice, which is considered 
to act directly on GPR119 in pancreatic α-cells. Thus, GPR119 agonists may be able to reduce 
the risk of hypoglycemia in insulin treatment. 
The mechanism of action of GPR119 is partly common to GLP-1 analogue and DPP-4 
inhibitors. In addition, GPR119 is similar to GPR40 in terms of directly promoting glucose 
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sensing insulin secretion from the pancreas. Improving dyslipidemia is one of the most 
distinctive features of GPR119 agonist. Overexpression of GPR119 regulates cholesterol 
transporter expression in the intestinal lumen and liver to reduce the lipid and inflammatory 
cytokine levels in apo-E deficient mice. Atherosclerotic lesion was also improved.11 Therefore, 
the GPR119 agonist is considered to be not only an anti-diabetic but a lipid-lowering drug. In 
fact, GSK1292263 had been developed as drug for dyslipidemia (NCT01218204). 
GPR119 agonists are often composed of three parts as follows: a piperidine or a piperazine 
ring N-substituted with a carbamate or a heteroaryl group at the right side, a phenyl group 
substituted with a methylsulfonyl or a heteroaryl group at the left side, and a linker part 
connecting the two parts. We focused on the piperidine ring on the right side of the structure 
(typical structure for example; MBX-2982, PSN119-2) and developed JTP-109192, which has 
a spirocyclic cyclohexane structure on the right side.12,13 JTP-109192 has high three-
dimensionality and potent GPR119 agonistic activity with no cytochrome P450 (CYP) 
inhibitory activity, and successed to optimize lipophilicity, solubility and agonistic activity.  
In the present study, this small molecule GPR119 agonist JTP-109192 enhanced GSIS and 
GLP-1 secretion in vitro and in vivo. After single administration of JTP-109192 at a dose of 
10 mg/kg in the ipGTT study in ZF rats, the plasma glucose levels were markedly decreased 
and the plasma insulin levels were elevated until 30 minutes after glucose administration. The 
plasma concentrations of JTP-109192 at 16 hours after administration of 10 mg/kg is thought 
to be sufficient to improve glucose tolerance in ZF rats. During 6 weeks of repeated 
administration, the plasma glucose and insulin levels were tended to be decreased in the JTP-
109192 10 mg/kg group as compared with the vehicle group. Furthermore, JTP-109192 
significantly improved the insulin sensitivity leading to suppression of hepatic gluconeogenesis. 
From these results, it is expected that JTP-1019192 will emerge as a potent new 
antihyperglycemic agent for the treatment of type 2 diabetes by improving GSIS and insulin 
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resistance, and be well tolerated on long-term administration. In the preliminary study, we 
evaluated some known GPR119 agonist and compared with our compound. MBX2982 and 
GSK1292263 showed similar features as JTP-109192 on GLP-1 secretion and insulin secretion 
in in vitro and glucose lowering effects in in vivo. For example, in the human GPR119 cAMP 
assay, the EC50 values of MBX2982 and GSK1292263 were 0.7 nmol/L and 9.0 nmol/L, 
respectively. In the GLUTag cells, the GLP-1 secretory effect of MBX2982 was potent and 
effective from 0.1 μmol/L, but was weaker than JTP-109192. In the INS1E cells, the 
insulinotropic effect of MBX2982 was enhanced from 0.1 μmol/L at 11.2 mmol/L glucose 
condition. In the glucose tolerance test, the glucose lowering effect of JTP-109192 was similar 
to MBX2982 at 30 mg/kg and was more potent compared with GSK1292263. Based on these 
results from known GPR119 agonists which have different chemotype from our compound, 
JTP-109192 has potent but same mode of action as GPR119 agonist. 
The GPR119 is expressed in pancreatic β-cells and intestinal L-cells.4 The OEA, a natural 
GPR119 agonist, is well known to enhance GSIS and GLP-1 secretion by elevating intracellular 
cAMP levels.14 In our study, the hyperglycemic clamp test was performed in SD rats to 
investigate whether JTP-109192 can enhance GSIS at different blood glucose levels, 250 and 
400 mg/dL. The former condition mimics the postprandial plasma glucose levels of impaired 
glucose tolerant (IGT) subjects and the latter mimics those of type 2 diabetic subjects. The first 
and second insulin secretion enhancement by JTP-109192 was in accordance with the elevation 
of blood glucose levels from 250 mg/dL to 400 mg/dL. On the other hand, no insulinotropic 
effect of JTP-109192 was observed before glucose infusion (within normal blood glucose 
levels). Taken together, these findings suggest that JTP-109192 enhances insulin secretion with 
little risk of hypoglycemia, which is often observed with SUs treatment.15 We have already 
reported the structure-activity relationships of GPR119 agonist and its glucose lowering effect 
with GSIS enhancement 0.5 hour after single administration in the ipGTT in SD rats.12 
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Meanwhile, the glucose lowering effect of repeated administration on insulin resistant animals 
has not been evaluated. However, such an evaluation is critical in the development of GPCRs 
agonist because it seems that repeated administration of GPR119 agonists leads to 
tachyphylaxis.16 
The tachyphylaxis is reported in several GPR119 agonists such as GSK1292263 and JNJ-
38431055.17 In clinical trials, GSK1292263 did not increase blood active GLP-1 secretion and 
failed to control blood glucose levels.7 However, in the preclinical experiment, GSK1292263 
maintained its glucose lowering effect after repeated dosing.18 Therefore, it is suspected that 
the translational research from rat to human was not sufficient. To elucidate our hypothesis, we 
compared GSK1292263 and JTP-109192 in in vitro. Our preliminary results showed that the 
pretreatment of hGPR119 by GSK1292263 reduced cAMP induction by second treatment of 
GSK1292263 by 43% as compared with the response without pretreatment. On the other hand, 
cAMP induction after JTP-109192 pretreatment showed only 23% decrease (data not shown). 
These results are similar to the report of Hothersal et al.19 Therefore, we speculate that the 
different degree of desensitization of GPR119 agonism is one of the reasons of tachyphylaxis. 
Taking into account that repeated administration of JTP-109192 improved insulin sensitivity 
with increasing plasma levels of active GLP-1 in ZF rats, it is indicated that JTP-109192 may 
not cause tachyphylaxis for at least the 6 weeks administration.  
Single administration of JTP-109192 had no effect on insulin sensitivity at any infusion 
insulin levels (data not shown). Accordingly, it is considered that JTP-109192 ameliorates 
insulin resistance secondarily to its glucose lowering effect, which is in part due to a decrease 
of hepatic glucose production. The mechanism underlying the decrease requires further 
investigation. The suppression of plasma glucagon levels by JTP-109192 treatment under 
normoglycemic conditions (data not shown) may provide one explanation. It is also reported 
that the increase of GLP-1 suppresses the expression of hepatic genes such as 
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phosphoenolpyruvate carboxykinase or glucose 6-phosphatase involved in glucose 
production.20 
In conclusion, JTP-109192 is a highly potent GPR119 agonist that enhances GSIS in INS1E 
cells and enhances GLP-1 secretion in GLUTag cells in vitro. In in vivo study, a single 
administration of JTP-109192 improves glucose tolerance. Repeated administration of JTP-
109192 for 6 weeks improved glucose metabolism and improved insulin sensitivity in ZF rats 
without lack of drug efficacy. These results suggest that JTP-1019192 represents a new potential 
antihyperglycemic agent that can be used for treatment of type 2 diabetes without causing 
tachyphylaxis. 
 
4. Materials and methods 
4.1 Animals 
Animals were treated in accordance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978). Animal study 
protocols were approved by the Institutional Animal Care and Use Committee of the Central 
Pharmaceutical Research Institute, Japan Tobacco Inc. SD and ZF rats were purchased from 
Charles River Laboratories Japan, Inc. (Yokohama, Japan). Husbandry conditions were 
maintained as follows: temperature of 23.0 ± 3.0°C, humidity of 55 ± 15%, 12 hour:12 hour 
light:dark cycle (lights on at 8 a.m., lights off at 8 p.m.), CRF-1 pelletized diet (Oriental Yeast 
Co., Ltd., Tokyo, Japan) supplied ad libitum, and UV-irradiated tap water supplied ad libitum. 
 
4.2 Articles and cell lines 
The proceedings of structure-activity relationships of GPR119 agonist development has been 
previously reported.12 The test article JTP-109192, 4-[5-(3,3-dimethyl-2-oxa-spiro[4,5] dec-8-
yl)-pentyloxy]-N,N-dimethyl-benzamide, was one of the candidates to be synthesized in the 
Central Pharmaceutical Research Institute of Japan Tobacco Inc. (Osaka, Japan). JTP-109192 
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or other compounds were dissolved in dimethyl sulfoxide (DMSO) (Nacalai Tesque, Inc, Japan) 
and used as a vehicle in cell-based assays. Metolose® SM-1500 (methylcellulose) (Shin-Etsu 
Chemical Co., Ltd, Japan) in a 0.5% aqueous solution was used as a vehicle in animal studies. 
The rat pancreatic β-cell line INS1E was licensed from Wolheim & Maechier Experimental 
Diabetology Unit, Department of Cell Physiology and Metabolism, University Medical Center 
(Geneva, Switzerland). The murine enteroendocrine cell line GLUTag cells was licensed from 
Ontario Inc. (Toronto, Canada).  
 
4.3 GPR119 agonist activity assay 
GPR119 agonist activity was evaluated in HEK293 cells overexpressing human and rat 
GPR119 using a cAMP HiRange assay kit (Cisbio, Japan). The test articles in stimulation buffer 
[Hanks’ Balanced Salt Solution, 20 mM HEPES, 0.1% bovine serum albumin, 0.1 mM IBMX 
and 0.1 mM Ro 20-1724, (cAMP-specific phosphodiesterase type IV inhibitor)] were plated in 
96-well half-area plates. The cells were plated on to the plates at 12,500 cells/well in buffer mix 
then incubated for 30 minutes at room temperature. Thereafter, anti-cAMP cryptate conjugate 
was added to the wells and incubated for 3 hours at room temperature in the dark. The cellular 
cAMP levels were measured using a micro plate reader. The EC50 value of JTP-109192 was 
determined as the concentration of the test compound required to achieve 50% of the maximal 
OEA stimulated response. 
 
4.4 Insulin secretion from INS1E cells 
The rat pancreatic β-cell line INS1E cells was maintained in Roswell Park Memorial Institute 
(RPMI) medium supplemented with 5 mmol/L glucose and 4.5% FBS and aerated in a 5%:95% 
CO2:air mixture at 37°C. The cells were plated into 24-well plates at the density of 
3 × 105cells/well and grown for 2 days. After medium was removed by aspirating, the cells 
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were washed twice with Krebs-Ringer bicarbonate (KRB) buffer containing 3.3 mmol/L 
glucose and then incubated for 2 hours at 37°C. The cells were then incubated with JTP-109192 
(0.001–1 μmol/L) for 2 hours at 37°C. The supernatant was collected to measure the insulin 
concentration using a rat insulin ELISA kit (Morinaga Institute of Biological Science, Inc, 
Japan). 
 
4.5 GLP-1 secretion from GLUTag cells 
The murine enteroendocrine cell line GLUTag cells was maintained in Dulbecco's Modified 
Eagle's Medium (DMEM) (low glucose) supplemented with 1% penicillin-streptomycin and 
10% FBS, and aerated in a 5%:95% CO2:air mixture at 37°C. The cells were plated into 24-
well plates at the density of 1.25 × 105 cells/well and grown for 3 days. After medium was 
removed by aspirating, the cells were washed twice with KRB buffer and incubated with JTP-
109192 (0.001–10 μmol/L) for 2 hours at 37°C. The supernatant was collected to measure the 
active GLP-1(7-36, 7-37) concentration using a GLP-1 ELISA kit (LINCO. Research Inc, USA). 
 
4.6 Intraperitoneal glucose tolerance test after single and repeated administration in 
Zucker Fatty rat 
ZF rats (9 weeks old) were orally administered 0.5% methyl-cellulose (vehicle) or JTP-109192 
(3 or 10 mg/kg) and fasted. After 16 hours, rats were intraperitoneally administered glucose 
(2 g/kg). The blood samples were collected from the tail vein into heparinized tubes at 0 (prior 
to glucose administration), 30, 60 and 120 minutes after glucose administration to measure the 
plasma glucose concentrations, and at 0, 7, 30, 60 and 120 minutes to measure the plasma 
insulin concentrations. The insulinogenic index was calculated according to the following 
equation: 
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Insulinogenic index = the area under the curve (AUC) values of plasma insulin from base line 
and from 0 to 30 minutes ⁄ the AUC values of plasma glucose from base line and from 0 to 
30 minutes. 
 
4.7 Repeated treatment in Zucker Fatty rat 
Twelve male ZF rats (9 weeks old) were selected from 30 rats as follows. Four days before the 
start of administration, blood samples were collected from the tail vein into heparinized tubes 
and inverted to mix and the hemoglobin A1c (HbA1c) levels were determined. Remaining part 
of each blood sample was then centrifuged at 10,000 × g at 4°C for 5 minutes to obtain plasma 
sample and the plasma glucose and insulin concentrations were measured. On the day of the 
start of the administration, the body weights were measured. After excluding 18 rats with outlier 
values for these parameters from the group allocation, 12 rats were assigned to 2 groups with 
6 rats in each group (JTP-109192 10 mg/kg or vehicle group) so that no bias occurred in those 
parameters between the 2 groups. On day 1 and 28, ipGTT was performed. On day 40 to 42, 
the hyperinsulinemic euglycemic clamp test was performed. 
 
4.8 Operation (carotid artery and jugular vein cannulation) for glucose clamp test 
SD or ZF rats were anesthetized with isoflurane. After cervical incision, cannulas (SP 45, 
Natsume Seisakusho Co., Ltd., Japan) were inserted into the right jugular vein (for glucose and 
insulin infusion) and the left carotid artery (for blood collection), and fastened to the blood 
vessels by suture. These two cannulas were exteriorized through the skin at the back of the neck. 
The incisions were sutured and sprayed with antibiotic (kanamycin, Meiji Seika Pharma Co., 
Ltd., Japan). The cannulas were filled with a heparin sodium solution. After cannulation, rats 
were fasted overnight. 
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4.9 Hyperglycemic Clamp Test in Sprague Dawley rat 
At 30 minutes before the glucose infusion, 0.5% methyl-cellulose (vehicle) or JTP-109192 
(10 mg/kg) was administered orally to conscious, freely moving, cannulated SD (7 week old) 
rats. Blood was collected via the carotid artery cannula to measure the blood glucose 
concentrations using a compact blood glucose analyzer (Antosense III, HORIBA, Ltd., Japan) 
every 10 minutes from 40 minutes before starting glucose infusion. 25% glucose solution was 
infused via the jugular vein cannula for one minute (equivalent to 150 mg/kg) using a syringe 
pump (Econoflo Syringe Pump, Harvard Bioscience, Inc., USA). The blood glucose 
concentrations were monitored at two and five minutes and thereafter every five minutes up to 
60 minutes after the start of glucose infusion (0 minutes), and were maintained at approximately 
250 mg/dL by adjusting the infusion rate of the glucose solution. After blood collection at 
60 minutes, the glucose solution was infused via the jugular vein cannula over one minute 
(equivalent to 300 mg/kg). The blood glucose concentrations were then monitored at 62 and 
65 minutes and thereafter every five minutes up to 120 minutes after the start of glucose 
infusion, and were maintained at approximately 400 mg/dL by adjusting the infusion rate of the 
glucose solution. Blood samples were collected into a heparinized tube to measure the plasma 
insulin concentrations at 40, 30, 20, and 10 minutes before the glucose infusion, at the start of 
glucose infusion, and at 2, 5, 10, 20, 30, 40, 50, 60, 62, 65, 70, 80, 90, 100, 110, and 120 minutes 
after the start of glucose infusion. The blood was centrifuged (4°C, 10,000 × g, 5 minutes) to 
obtain plasma. The plasma was stored at –20ºC until measurement of insulin concentrations. 
The first phase insulin secretion was calculated from the area under the curve (AUC) of plasma 
insulin concentrations monitored for first five minutes of glucose infusion at each blood glucose 
level. The second phase insulin secretion was calculated from the AUC of plasma insulin 
concentrations monitored for remaining 55 minutes of glucose infusion at each blood glucose 
level. 
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4.10 Hyperinsulinemic-Euglycemic Clamp Test in Zucker Fatty rat 
A bolus dose of insulin (3.2 U/kg) was injected via the jugular vein cannula, followed by 
continuous infusion of insulin solution at the rates of 15 mU/kg/min using a syringe pump. 
Thereafter, a single drop of blood was collected via the carotid artery cannula every 5 minutes 
to monitor the blood glucose concentrations to adjust the infusion rate of the 25% glucose 
solution via the jugular vein cannula using a compact blood glucose analyzer (Medisafe Mini, 
Terumo Corporation, Japan). The steady-state was defined as the condition in which the blood 
glucose level was maintained at 110 ± 10 mg/dL without any alteration in glucose infusion rate 
for 10 minutes (3 consecutive glucose monitoring points). At the next 3 points of the steady-
state, blood samples were collected into heparinized tubes to determine the plasma insulin 
concentrations during the clamp period. The blood samples during the clamp periods were 
immediately centrifuged to obtain plasma samples. The plasma samples were stored at –20ºC 
until measurement of plasma insulin concentrations. The glucose infusion rate was calculated 
in accordance with the following equation: 
Glucose infusion rate (mg/kg/min) = Infusion rate of 25% glucose solution (mL/hr) during the 
clamp period × 250 (mg/mL) ⁄ 60 ⁄ body weight (kg) 
 
4.11 Hyperinsulinemic-Euglycemic Clamp Test in Zucker Fatty rat (using [3-3H] glucose 
to determine hepatic glucose production) 
A bolus dose of [3-3H] glucose solution (740 kBq/rat) was injected via the jugular vein cannula, 
followed by continuous infusion at the rate of 7.4 kBq/min. At 110, 115 and 120 minutes after 
the start of [3-3H] glucose infusion, a single drop of blood was collected via the carotid artery 
cannula to measure the blood glucose concentrations using a compact blood glucose analyzer 
(Medisafe Mini, Terumo Corporation, Japan). Blood samples were also collected into 
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heparinized tubes via the carotid artery cannula to determine the plasma insulin concentrations 
and radioactivity of the [3-3H] glucose during the basal period. Immediately after the last blood 
sampling, a bolus dose of insulin (3.2 U/kg) was injected via the jugular vein cannula, followed 
by continuous infusion of [3-3H] glucose and insulin solution at the rates of 7.4 kBq/min and 
15 mU/kg/min, respectively. Thereafter, a single drop of blood was collected via the carotid 
artery cannula every 5 minutes to monitor the blood glucose concentrations to adjust the 
infusion rate of the 25% glucose solution via the jugular vein cannula. The steady-state was 
defined as above. The next 3 points of the steady-state, blood samples were collected into 
heparinized tubes to determine the plasma insulin concentrations and radioactivity of the [3-
3H] glucose during the clamp period. The plasma samples were stored at –20ºC until 
measurement of the plasma insulin concentrations and radioactivity of the [3-3H] glucose. 
 
4.12 Measurement of the radioactivity of [3-3H] glucose and calculation of hepatic 
gluconeogenesis 
Exactly 200 µL of 0.3 mol/L zinc sulfate solution and 180 µL of 0.3 mol/L barium hydroxide 
solution were added to 20 µL of plasma and thoroughly mixed. The mixture was centrifuged 
(10,000 × g, for 5 minutes, 15°C) and 200 µL of the 360 µL of the supernatants were transferred 
to other tubes and evaporated to dryness for removing water including 3H2O by heating to 100ºC 
under a nitrogen gas flow. The residue was rehydrated with 300 µL of purified water and 
thoroughly mixed with 3 mL of liquid scintillation cocktail (Clear-sol I, Nacalai Tesque, Inc., 
Japan) to measure the radioactivity of the [3-3H] glucose using a liquid scintillation counter 
(TRI-CARB 2500TR, PACKARD, USA). 
The suppression of hepatic gluconeogenesis was calculated in accordance with the following 
equation: 
Rd (mg/kg/min) = Ra (Rate of glucose appearance) = infusion rate of [3-3H] glucose 
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(dpm/min) ⁄ specific activity of [3-3H] glucose (dpm/mg) ⁄ body weight (kg) 
Specific activity of [3-3H] glucose (dpm/mg) = radioactivity concentration of [3-3H] glucose 
(dpm/mL) ⁄ plasma glucose level (mg/dL) × 100 
Hepatic gluconeogenesis (mg/kg/min) = Ra (mg/kg/min) – glucose infusion rate (mg/kg/min) 
Suppression of hepatic gluconeogenesis (%) = 100 – hepatic gluconeogenesis (mg/kg/min) ⁄ 
Basal hepatic gluconeogenesis (mg/kg/min) × 100 
 
4.13 Biological parameters 
Food intake, body weight, and blood biochemical parameters (HbA1c, plasma glucose and 
insulin) were evaluated every week. Blood samples were collected from the tail veins of rats. 
Glucose concentrations were measured using a commercial kit (Roche Diagnostics, 
Switzerland) and an automatic analyzer (Hitachi, Japan). Insulin concentrations were measured 
using an ELISA kit. Total hemoglobin and total HbA1c concentrations were determined using 
commercial kits and an automatic analyzer. 
 
4.14 Statistical analyses 
The significance tests were performed using the following procedures: for comparisons 
between 2 groups, homogeneity of variance was tested with an F-test; subsequently, the 
Student’s t-test or Aspin-Welch’s t-test was performed for homoscedastic data or 
heteroscedastic data, respectively. For comparisons between 3 or more groups, homogeneity of 
variance was tested with the Bartlett’s test; subsequently, the Dunnett’s test or Steel test was 
performed for homoscedastic data or heteroscedastic data, respectively. A 2-tailed significance 
level of 5% was used. SAS System version 8.2 and SAS Preclinical Package version 5.0 (SAS 
Institute Japan Inc., Tokyo, Japan) were used for all statistical analysis. 
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Figure 1. The GPR119 agonist activity of JTP-109192 in HEK293 cells expressing stable 
human, rat and mouse GPR119 protein. Oleoylethanolamide (OEA), a natural GPR119 agonist, 
was used as a reference compound. The EC50 value was determined as the concentration of the 
test compound required to achieve 50% of the maximal OEA stimulated response.  
(A) Chemical structure of JTP-109192. The concentration-response curves of JTP-109192 on 
intracellular cAMP in HEK293 cells expressing human (B), rat (C) and mouse (D) GPR119 
protein. Data are presented as the mean ± standard error of the mean of the EC50 values in four 
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Figure 2. The effects of JTP-109192 on insulin secretion in INS1E cells and GLP-1 secretion 
in GLUTag cells. 
(A) shows the concentration-response curves of JTP-109192 on insulin secretion in INS1E cells 
at 3.3 and 11.2 mmol/L glucose condition. Data are presented as the mean ± standard deviation; 
n = 4. $P < 0.05 vehicle at 3.3 mmol/L vs. vehicle at 11.2 mmol/L group (Student’s t-test); 
*P < 0.05 vs. vehicle group (Dunnett’s test). (B) shows the concentration-response curves of 
JTP-109192 on GLP-1 secretion in GLUTag cells. Data are presented as the mean ± standard 
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Figure 3. The effects of JTP-109192 on insulin secretion in SD rats after single administration 
using hyperglycemic clamp technique. 
(A) shows the blood glucose levels at 250 and 400 mg/dL by adjusting infusion rate of the 
glucose solution. (B) shows the plasma insulin levels during the hyperinsulinemic euglycemic 
clamp test. (C) shows first phase insulin secretion. (D) shows second phase insulin secretion. 
(E) shows plasma GLP-1 levels in the portal and peripheral veins. Data are presented as the 
mean ± standard deviation; n = 5–6. ††P < 0.01 vehicle group at 400 mg/dL vs. 250 mg/dL 
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Figure 4. The effect of JTP-109192 on body weight, food intake, plasma glucose and plasma 
insulin levels in ZF rats. 
(A) shows the body weight during the repeated administration. No change were observed 
between JTP-109192 10 mg/kg and vehicle groups. (B) shows the plasma glucose levels during 
the repeated administration. (C) shows the plasma insulin levels during the repeated 
administration. (D) shows the blood HbA1c levels on day 40. Data are expressed as the 
mean ± standard deviation; n = 6. *P < 0.05 vs. vehicle group (Student’s t-test). 
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Figure 5. The effects of JTP-109192 on intraperitoneal glucose tolerance test after single 
administration in ZF rats.  
(A) shows the plasma glucose levels during the glucose tolerance test. (B) shows the plasma 
insulin levels during the glucose tolerance test. (C) shows the insulinogenic index during the 
glucose tolerance test. Data are expressed as the mean ± standard deviation; n = 6. *P < 0.05, 
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Figure 6. The effects of JTP-109192 on intraperitoneal glucose tolerance test after repeated 
administration in ZF rats.  
(A) shows the plasma glucose levels during the glucose tolerance test (B) shows the plasma 
insulin levels during the glucose tolerance test. (C) shows the insulinogenic index during the 
glucose tolerance test. Data are expressed as the mean ± standard deviation; n = 6. *P < 0.05, 
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Figure 7. The effects of JTP-109192 on insulin sensitivity after repeated administration in ZF 
rats. 
(A) shows the plasma GLP-1 levels in peripheral vein. (B) shows the glucose infusion rates 
during the hyperinsulinemic euglycemic clamp test. Data are expressed as the mean ± standard 
deviation; n = 6 rats. (C) shows the suppression of hepatic gluconeogenesis during the 
hyperinsulinemic euglycemic clamp test. Data are expressed as the mean ± standard deviation; 
n = 8. *P < 0.05 vs. vehicle group (Student’s t-test).  
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